Targets › PTGFR
8 programs from 8 companies in 16 trials: 7 Phase 4, 6 Phase 3, 2 Phase 1, 1 Phase 2; Ophthalmology, Immunology; next expected readout Dec 2026.
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. (UniProt, P43088)
Open in Phaseline: the race on PTGFR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Copenhagen University Hospital, Rigshospitalet | Monoprost Prostaglandin F2α analog | PTGFR | Phase 4 | Glaucoma | Dec 2026 |
| Glaukos | Travoprost Prostanoid FP receptor agonist | PTGFR | Phase 4 | Glaucoma, Open-Angle; Glaucoma, Open-angle; Glaucoma; Open Angle Glaucoma | May 2027 |
| Prairie Eye Center | Rocklatan Prostaglandin F receptor agonist and Rho kinase inhibitor | PTGFR | Phase 4 | Open Angle Glaucoma | – |
| Federal University of São Paulo | Triplenex (triple fixed combination) Triple combination: alpha-2 adrenergic agonist (brimonidine), non-selective beta-blocker ( | ADRA2A, ADRB1, ADRB2, PTGFR | Phase 4 | Glaucoma | – |
| YS Life Science | YSBP Prostaglandin F (FP) receptor agonist | PTGFR | Phase 3 | Primary Open Angle Glaucoma (POAG) | Nov 2027 |
| SpyGlass Pharma | Bimatoprost Prostanoid FP receptor agonist | PTGFR | Phase 3 | Cataract; Glaucoma | Nov 2027 |
| Triple Hair | TH07 Fixed combination of 5-alpha reductase inhibitor (finasteride), alpha-adrenergic agonist ( | SRD5A2, PTGFR | Phase 3 | Androgenic Alopecia | Dec 2027 |
| Santen Pharmaceutical | DE-117B Eye Drops Prostaglandin F (FP) receptor agonist | PTGFR | Phase 3 | Open Angle Glaucoma | – |
Glaucoma (5) Cataract (4) Open Angle Glaucoma (3) Glaucoma, Open-Angle (1) Glaucoma, Open-angle (1) Primary Open Angle Glaucoma (POAG) (1) Androgenic Alopecia (1)
small molecule (6), mixed (1)
Federal University of São Paulo (1) Copenhagen University Hospital, Rigshospitalet (1) SpyGlass Pharma (1) Glaukos (1) YS Life Science (1) Prairie Eye Center (1) Santen Pharmaceutical (1) Triple Hair (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.